FRM
CBAY

Fox Run Management’s Cymabay Therapeutics CBAY Stock Holding History

Fox Run Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-24,852
Closed -$323K – 960
2018
Q1 		$323K Buy
+24,852
New +$309K 0.08% 468

Other funds holding CBAY

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Fox Run Management's CBAY Position: Q2 2018 in Review

Fox Run Management sold out of Cymabay Therapeutics (CBAY) in Q2 2018, closing a stake of 24,852 shares — an estimated $323K sold.

Fox Run Management first reported a position in CBAY in Q1 2018 and held it in 1 quarter. The position peaked at $323K in Q1 2018. 118 funds tracked by Wall St. Rank hold CBAY as of Q2 2018.

  • Fox Run Management reported no remaining Cymabay Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Fox Run Management sold 24,852 Cymabay Therapeutics shares in Q2 2018, an estimated $323K.
  • Fox Run Management first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 1 quarter.
  • Fox Run Management's Cymabay Therapeutics position peaked at $323K in Q1 2018.
  • 118 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2018.

Based on Fox Run Management's 13F filing for Q2 2018, filed 17 Jul 2018.